Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study terminated early due to slow enrollment that significantly extended the expected study duration.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate the restoration and maintenance of thoracic kyphosis and coronal curve correction demonstrated through the surgical implantation of the K2M MESA Railâ„¢ Deformity System as compared to literature reported outcomes for standard Cobalt Chrome (CoCr) rod systems in the treatment of Adolescent Idiopathic Scoliosis (AIS).
Patients treated with the Ø5.5mm or Ø4.5mm MESA Rail™ Deformity System that had:
Diagnosis of AIS requiring surgical treatment for selective non-cervical fusion with a minimum of five (5) instrumented vertebrae between T1-S1 as confirmed by patient history and radiographic studies.
AIS cases must be classified as a Lenke type 1 or type 2 curve (lumbar modifiers and thoracic sagittal profiles will be noted but not restrictive).
Age at time of surgery of ≥ 11 years old and ≤ 21 years old.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| AIS | Surgical implantation of the K2M MESA Railâ„¢ Deformity System in the treatment of Adolescent Idiopathic Scoliosis (AIS). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MESA Railâ„¢ Deformity System | Device | MESA Railâ„¢ (cross-sectioned rod) with MESA pedicle screws compared to traditional rod use in the literature |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Thoracic Kyphosis and Coronal Curve Correction on X-ray at 24 Months | Restoration and maintenance of thoracic kyphosis and coronal curve correction. Thoracic kyphosis (Coronal Curve): measurement of curvature from the upper endplate of T4 to the lower endplate of T12. | Baseline (up to 90 days before surgery), 24 months |
| Number of Participants With Adverse Events | Number of participants with SAE and AE for the various intervals | Up to 24 months |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Pain Scores on the Visual Analog Scale (VAS) at 24 Months | Evaluation of the improvement of the Back VAS and Hip/Leg VAS (assessed together) at the 24 month post-operative visit as compared to pre-op time periods. Information on all reports of pain/numbness /tingling and the location of symptoms were captured and evaluated. VAS scale ranged from 0 - 100mm with the 100mm accounting for the highest level of pain. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Two-hundred four (204) total subjects with the MESA Rail Deformity System at up to 18 clinical sites, geographically distributed worldwide.
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 10870143 | Background | Wattenbarger JM, Richards BS, Herring JA. A comparison of single-rod instrumentation with double-rod instrumentation in adolescent idiopathic scoliosis. Spine (Phila Pa 1976). 2000 Jul 1;25(13):1680-8. doi: 10.1097/00007632-200007010-00011. | |
| 20505560 | Background | Newton PO, Yaszay B, Upasani VV, Pawelek JB, Bastrom TP, Lenke LG, Lowe T, Crawford A, Betz R, Lonner B; Harms Study Group. Preservation of thoracic kyphosis is critical to maintain lumbar lordosis in the surgical treatment of adolescent idiopathic scoliosis. Spine (Phila Pa 1976). 2010 Jun 15;35(14):1365-70. doi: 10.1097/BRS.0b013e3181dccd63. |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | K2M MESA Rail™ Deformity System | Patients treated with the Ø5.5mm or Ø4.5mm MESA Rail Deformity System that had:
|
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Demographics and Baseline Characteristics | This is a demographic and baseline characteristics of the patient population. This includes parameters such as Age, Gender, Height, Weight Body Mass Index (BMI) and Tobacco Usage. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change From Baseline in Thoracic Kyphosis and Coronal Curve Correction on X-ray at 24 Months | Restoration and maintenance of thoracic kyphosis and coronal curve correction. Thoracic kyphosis (Coronal Curve): measurement of curvature from the upper endplate of T4 to the lower endplate of T12. | 98 of the 99 participants who returned at 24 Months had the thoracic kyphosis measurement. | Posted | Mean | 95% Confidence Interval | degrees | Baseline (up to 90 days before surgery), 24 months |
|
|
From Operative to 24+ Months
Any untoward medical occurrence in a subject undergoing surgery in this trial which does not necessarily have a causal relationship with this intervention. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the one of the devices. Any AE that occurs during the subject's participation in the study will be recorded on the Adverse Event case report form.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Participants With Adverse Events | Overall participants with any AE or SAE. 5 of the 17 SAE participants did not experience a non-SAE events. The other 12 participants had events in both categories. The study did not establish a frequency threshold, therefore, all AEs are listed. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Infectious mononucleosis | Blood and lymphatic system disorders | MedDRA (Unspecified) | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anaemia | Blood and lymphatic system disorders | MedDRA (Unspecified) | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Marissa Conrad, Senior Director of Clinical and Medical Affairs | Stryker Spine | 201-749-8162 | marissa.conrad@stryker.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | May 21, 2014 | Mar 3, 2021 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D012600 | Scoliosis |
| D013121 | Spinal Curvatures |
| D013122 | Spinal Diseases |
| ID | Term |
|---|---|
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Baseline (up to 90 days before surgery), 24 months |
| Change From Baseline in Quality of Life Scores on the SRS-22r at 24 Months | The Revised Scoliosis Research Society-22 (SRS-22r) is a specific questionnaire for spine conditions. It is applied to patients with idiopathic scoliosis, whose conditions and treatments have a great impact on their quality of life. The SRS 22r was created and revised with the purpose of evaluating this impact from the patient's point of view. The reviewed version contains 22 questions distributed into five domains: function/activity (FA), pain (P), self- image/appearance (SA), mental health (MH) and satisfaction with treatment (ST). The scores vary from 1 to 5 in which 5 is the best health quality of life of patients. | Baseline (up to 90 days before surgery), 24 months |
| Patient Satisfaction | At the 12 month and 24 month follow-up visits, subjects were asked whether they were satisfied with the outcome of their surgery (Yes/No) and whether they would repeat the operation (Yes/No). | 12 months and 24 months |
| Investigator's Rating of Subject's Clinical Disposition Using Odom's Criteria | At the 24 month follow-up visit, the Investigator rated the clinical disposition of each study subject according to Odom's Criteria as follows: Excellent: all pre-operative symptoms relieved, able to carry out daily occupations without impairment. Good: minimum persistence of pre-operative symptoms, able to carry out daily occupations without significant interference. Fair/Satisfactory: relief of some pre-operative symptoms but physical activity is significantly limited. Poor: symptoms or signs unchanged or worsened. | 24 months |
| Length of Surgery Time | The length of the surgical procedure from the initial incision to final closure were captured. | During surgery |
| Length of Anesthesia Time | The length of time the patient is under anesthesia was captured. | During surgery |
| Estimated Blood Loss | The amount of blood loss over the entire length of the surgery was captured. | During surgery |
| Length of Hospital Stay | The length of the hospital stay from the date of admission to the date of discharge. | Admission to Discharge |
| Change in Percentage of Participants Able to Return to Work/School | The ability to and the time it takes for the subject to be cleared to return to work/school from the date of surgery by looking at the change in percentage of participants who were able to return to work without any restrictions | Pre-Op to 24 months |
| Use of Narcotics Post-surgery | The types and dosages of any narcotics taken by the patient pre- and post-surgery was documented. | Pre-Op to 24 months |
| 18007253 | Background | Kim YJ, Lenke LG, Bridwell KH, Kim J, Cho SK, Cheh G, Yoon J. Proximal junctional kyphosis in adolescent idiopathic scoliosis after 3 different types of posterior segmental spinal instrumentation and fusions: incidence and risk factor analysis of 410 cases. Spine (Phila Pa 1976). 2007 Nov 15;32(24):2731-8. doi: 10.1097/BRS.0b013e31815a7ead. |
| Participants |
|
| Age, Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | The study Case Report Forms did not include Race/Ethnicity | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Height | Mean | Standard Deviation | cm |
|
| Weight | Mean | Standard Deviation | kg |
|
| Body Mass Index (BMI) | Mean | Standard Deviation | kg/m^2 |
|
| Tobacco Use | Count of Participants | Participants |
|
| Participants |
|
|
| Primary | Number of Participants With Adverse Events | Number of participants with SAE and AE for the various intervals | This is an analysis of the number of participants that reported any form of adverse event. Overall participants with any AE or SAE. 5 of the 17 SAE participants did not experience a non-SAE events. The other 12 participants had events in both categories. The study did not establish a frequency threshold, therefore, all AEs are listed. | Posted | Number | participants | Up to 24 months |
|
|
|
| Secondary | Change From Baseline in Pain Scores on the Visual Analog Scale (VAS) at 24 Months | Evaluation of the improvement of the Back VAS and Hip/Leg VAS (assessed together) at the 24 month post-operative visit as compared to pre-op time periods. Information on all reports of pain/numbness /tingling and the location of symptoms were captured and evaluated. VAS scale ranged from 0 - 100mm with the 100mm accounting for the highest level of pain. | 13 out of the 99 participants who returned at 24 months, did not complete the survey. | Posted | Mean | Standard Deviation | score on a scale | Baseline (up to 90 days before surgery), 24 months |
|
|
|
| Secondary | Change From Baseline in Quality of Life Scores on the SRS-22r at 24 Months | The Revised Scoliosis Research Society-22 (SRS-22r) is a specific questionnaire for spine conditions. It is applied to patients with idiopathic scoliosis, whose conditions and treatments have a great impact on their quality of life. The SRS 22r was created and revised with the purpose of evaluating this impact from the patient's point of view. The reviewed version contains 22 questions distributed into five domains: function/activity (FA), pain (P), self- image/appearance (SA), mental health (MH) and satisfaction with treatment (ST). The scores vary from 1 to 5 in which 5 is the best health quality of life of patients. | While 99 participants completed 24 month interval, 14 patients out of the 99 did not did not complete the survey. | Posted | Mean | Standard Deviation | score on a scale | Baseline (up to 90 days before surgery), 24 months |
|
|
|
| Secondary | Patient Satisfaction | At the 12 month and 24 month follow-up visits, subjects were asked whether they were satisfied with the outcome of their surgery (Yes/No) and whether they would repeat the operation (Yes/No). | Patient self-assessment of the procedure at 12M and 24M | Posted | Count of Participants | Participants | 12 months and 24 months |
|
|
|
| Secondary | Investigator's Rating of Subject's Clinical Disposition Using Odom's Criteria | At the 24 month follow-up visit, the Investigator rated the clinical disposition of each study subject according to Odom's Criteria as follows: Excellent: all pre-operative symptoms relieved, able to carry out daily occupations without impairment. Good: minimum persistence of pre-operative symptoms, able to carry out daily occupations without significant interference. Fair/Satisfactory: relief of some pre-operative symptoms but physical activity is significantly limited. Poor: symptoms or signs unchanged or worsened. | Patients who were rated based on the outcome of their treatment and would indicate either Excellent, Good or Fair/Satisfactory. No responses are shown under missing | Posted | Count of Participants | Participants | 24 months |
|
|
|
| Secondary | Length of Surgery Time | The length of the surgical procedure from the initial incision to final closure were captured. | 186 patients had their surgery times recorded. There were 3 additional procedures staged increasing the overall number of units analyzed to 189. | Posted | Mean | Standard Deviation | Minutes | During surgery | surgeries | surgeries |
|
|
|
| Secondary | Length of Anesthesia Time | The length of time the patient is under anesthesia was captured. | 183 subjects had anesthesia time included. There were 3 staged procedures increasing the overall number of units analyzed to 186. | Posted | Mean | Standard Deviation | Minutes | During surgery | surgeries | surgeries |
|
|
|
| Secondary | Estimated Blood Loss | The amount of blood loss over the entire length of the surgery was captured. | 187 patients had blood loss included. There were 3 additional procedures staged increasing the overall number of units analyzed to 190. | Posted | Mean | Standard Deviation | Cubic Centimeters | During surgery | surgeries | surgeries |
|
|
|
| Secondary | Length of Hospital Stay | The length of the hospital stay from the date of admission to the date of discharge. | 186 patients completed admit and discharge dates | Posted | Mean | Standard Deviation | Days | Admission to Discharge | surgeries | surgeries |
|
|
|
| Secondary | Change in Percentage of Participants Able to Return to Work/School | The ability to and the time it takes for the subject to be cleared to return to work/school from the date of surgery by looking at the change in percentage of participants who were able to return to work without any restrictions | Includes all participants who returned for each visit interval with those who did not respond to this question accounted for in the missing row. | Posted | Count of Participants | Participants | Pre-Op to 24 months |
|
|
|
| Secondary | Use of Narcotics Post-surgery | The types and dosages of any narcotics taken by the patient pre- and post-surgery was documented. | Includes all participants who returned for each visit interval with those who did not respond to this question accounted for in the missing row. | Posted | Count of Participants | Participants | Pre-Op to 24 months |
|
|
|
| 0 |
| 188 |
| 17 |
| 188 |
| 93 |
| 188 |
| Sickle cell anaemia with crisis | Blood and lymphatic system disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Abdominal Pain | Gastrointestinal disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Abdominal pain upper | Gastrointestinal disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Nausea | Gastrointestinal disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Vomiting | Gastrointestinal disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Complications associated with device | General disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Cyst | General disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Discomfort | General disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Cholecystitis | Hepatobiliary disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Infection | Infections and infestations | MedDRA (Unspecified) | Systematic Assessment |
|
| Pneumonia | Infections and infestations | MedDRA (Unspecified) | Systematic Assessment |
|
| Wound infection | Infections and infestations | MedDRA (Unspecified) | Systematic Assessment |
|
| Wound dehiscence | Injury, poisoning and procedural complications | MedDRA (Unspecified) | Systematic Assessment |
|
| Patellofemoral pain syndrome | Musculoskeletal and connective tissue disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Headache | Nervous system disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Motor dysfunction | Nervous system disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Sensory loss | Nervous system disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Device failure | Product Issues | MedDRA (Unspecified) | Systematic Assessment |
|
| Anxiety | Psychiatric disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Depression | Psychiatric disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Atelectasis | Respiratory, thoracic and mediastinal disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Medical device removal | Surgical and medical procedures | MedDRA (Unspecified) | Systematic Assessment |
|
| Infectious mononucleosis | Blood and lymphatic system disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Splenomegaly | Blood and lymphatic system disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Cardiac disorder | Cardiac disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Tachycardia | Cardiac disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Conjunctivitis | Eye disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Abdominal discomfort | Gastrointestinal disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Abdominal pain | Gastrointestinal disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Abdominal pain upper | Gastrointestinal disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Constipation | Gastrointestinal disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Diarrhoea | Gastrointestinal disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Functional gastrointestinal disorder | Gastrointestinal disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Nausea | Gastrointestinal disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Salivary gland mucocoele | Gastrointestinal disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Vomiting | Gastrointestinal disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Chest pain | General disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Chills | General disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Complication associated with device | General disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Cyst | General disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Flank pain | General disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Hypertrophy | General disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Pain | General disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Pyrexia | General disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Respiratory complication associated with device | General disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Swelling | General disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Drug hypersensitivity | Immune system disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Abscess | Infections and infestations | MedDRA (Unspecified) | Systematic Assessment |
|
| Infection | Infections and infestations | MedDRA (Unspecified) | Systematic Assessment |
|
| Influenza | Infections and infestations | MedDRA (Unspecified) | Systematic Assessment |
|
| Otitis externa | Infections and infestations | MedDRA (Unspecified) | Systematic Assessment |
|
| Otitis media | Infections and infestations | MedDRA (Unspecified) | Systematic Assessment |
|
| Pharyngitis streptococcal | Infections and infestations | MedDRA (Unspecified) | Systematic Assessment |
|
| Viral pharyngitis | Infections and infestations | MedDRA (Unspecified) | Systematic Assessment |
|
| Wound infection | Infections and infestations | MedDRA (Unspecified) | Systematic Assessment |
|
| Fall | Injury, poisoning and procedural complications | MedDRA (Unspecified) | Systematic Assessment |
|
| Incision site discharge | Injury, poisoning and procedural complications | MedDRA (Unspecified) | Systematic Assessment |
|
| Joint injury | Injury, poisoning and procedural complications | MedDRA (Unspecified) | Systematic Assessment |
|
| Limb injury | Injury, poisoning and procedural complications | MedDRA (Unspecified) | Systematic Assessment |
|
| Post procedural complication | Injury, poisoning and procedural complications | MedDRA (Unspecified) | Systematic Assessment |
|
| Road traffic accident | Injury, poisoning and procedural complications | MedDRA (Unspecified) | Systematic Assessment |
|
| Suture related complication | Injury, poisoning and procedural complications | MedDRA (Unspecified) | Systematic Assessment |
|
| Wound | Injury, poisoning and procedural complications | MedDRA (Unspecified) | Systematic Assessment |
|
| Wound dehiscence | Injury, poisoning and procedural complications | MedDRA (Unspecified) | Systematic Assessment |
|
| Blood calcium decreased | Investigations | MedDRA (Unspecified) | Systematic Assessment |
|
| Body temperature decreased | Investigations | MedDRA (Unspecified) | Systematic Assessment |
|
| Weight decreased | Investigations | MedDRA (Unspecified) | Systematic Assessment |
|
| Dehydration | Metabolism and nutrition disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Muscle spasm | Musculoskeletal and connective tissue disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Muscular weakness | Musculoskeletal and connective tissue disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Musculoskeletal chest pain | Musculoskeletal and connective tissue disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Musculoskeletal apin | Musculoskeletal and connective tissue disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Musculoskeletal stiffness | Musculoskeletal and connective tissue disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Myalgia | Musculoskeletal and connective tissue disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Neck pain | Musculoskeletal and connective tissue disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Pain in extremity | Musculoskeletal and connective tissue disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Patellofemoral pain syndrome | Musculoskeletal and connective tissue disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Pelvic deformity | Musculoskeletal and connective tissue disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Pseudarthrosis | Musculoskeletal and connective tissue disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Spinal disorder | Musculoskeletal and connective tissue disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Temporomandibular joint syndrome | Musculoskeletal and connective tissue disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Carpal tunnel syndrome | Nervous system disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Dizziness | Nervous system disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Dysaesthesia | Musculoskeletal and connective tissue disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Headache | Musculoskeletal and connective tissue disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Hypoaesthesia | Nervous system disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Migraine | Musculoskeletal and connective tissue disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Motor dysfunction | Nervous system disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Neuralgia | Nervous system disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Paraesthesia | Nervous system disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Poor quality sleep | Nervous system disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Spinal muscular atrophy | Nervous system disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Syncope | Nervous system disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Vertigo | Nervous system disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Device failure | Product Issues | MedDRA (Unspecified) | Systematic Assessment |
|
| Anxiety | Psychiatric disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Attention deficit/hyperactivity disorder | Psychiatric disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Bladder dysfunction | Renal and urinary disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Atelectasis | Respiratory, thoracic and mediastinal disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Musculoskeletal chest pain | Respiratory, thoracic and mediastinal disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Pleural effusion | Respiratory, thoracic and mediastinal disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Pneumomediastinum | Respiratory, thoracic and mediastinal disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Body tinea | Skin and subcutaneous tissue disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Dermatitis contact | Skin and subcutaneous tissue disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Erythema | Skin and subcutaneous tissue disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Folliculitis | Skin and subcutaneous tissue disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Kerion | Skin and subcutaneous tissue disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Pruritus | Skin and subcutaneous tissue disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Rash | Skin and subcutaneous tissue disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Skin irritation | Skin and subcutaneous tissue disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Incisional drainage | Surgical and medical procedures | MedDRA (Unspecified) | Systematic Assessment |
|
| Haematoma | Vascular disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Hypotension | Vascular disorders | MedDRA (Unspecified) | Systematic Assessment |
|
| Orthostatic hypotension | Vascular disorders | MedDRA (Unspecified) | Systematic Assessment |
|
The Institution/PI shall not disclose/use any confidential/proprietary information (CI) disclosed to/developed by the Institution during the study. Institution/PI agree to hold the results of the Study in confidence, and shall not disclose them except with prior written consent of K2M. Institution agrees to submit any Articles to K2M for review prior to publication and agrees to edit out any confidential information identified by K2M.
| Any AE : Procedure Related |
|
| Any AE : Device Related |
|
| Any AE : Mild |
|
| Any AE : Moderate |
|
| Any AE : Severe |
|
| Any SAE |
|
| Any SAE : Procedure Related |
|
| Any SAE : Device Related |
|
| Any SAE : Mild |
|
| Any SAE : Moderate |
|
| Any SAE : Severe |
|
| Not Reported |
|
| Repeat Procedure |
|
| Missing |
|
| Not attending work/school by choice |
|
| Unable to go due to back/leg pain/conditions |
|
| Attending work/school with some restrictions |
|
| Attending work/school with no restrictions |
|
| Missing |
|
| Non-narcotics or NSAIDS |
|
| Intermittent short-acting narcotics |
|
| Chronic daily short-acting narcotics |
|
| Chronic daily long-acting narcotics |
|
| IV or injected narcotics |
|
| Epidural/Facet injection |
|
| Missing |
|
| Non-Back Meds |
|